Chimeric Antigen Receptor NK-Cell Immunotherapy (CAR-NK) is one of the most promising anti-tumor treatments, and improving the return-in method of CAR-NK cells can improve the anti-tumor effect. This report is about NKG2D-CAR gene-modified NK cell tumor in patients with advanced rectal cancer under real-time ultrasound guidance.